Prognostic Value of the B12/CRP Index in Older Systemically Treatable Cancer Patients.
C-reactive protein
frailty
medical oncology
older patients
serum vitamin B12 level
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Dec 2021
30 Dec 2021
Historique:
received:
23
11
2021
revised:
21
12
2021
accepted:
27
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
While comprehensive geriatric assessment (CGA) in older patients treated for cancer assesses several related domains, it does not include standardized biological tests. The present study aimed to: (1) assess the prognosis value of the B12/CRP index (BCI) in a population of systemically treatable older patients with cancer and (2) analyze the association between BCI value and pre-existing geriatric frailty. We conducted a retrospective observational study between January 2016 and June 2020 at Marseille University Hospital. All consecutive cancer patients aged 70 years and over before initiating systemic therapy were included. Of the 863 patients included, 60.5% were men and 42.5% had metastatic stage cancer. Mean age was 81 years. The low-BCI group (≤10,000) had a significantly longer survival time than the mid-BCI (10,000 < BCI ≤ 40,000) and high-BCI (BCI > 40,000) groups (HR = 0.327, CI95% [0.26-0.42], A BCI > 10,000 would appear to be a good biological prognostic factor for poor survival times and pre-existing geriatric impairment in older cancer patients before they initiate systemic treatment.
Sections du résumé
BACKGROUND
BACKGROUND
While comprehensive geriatric assessment (CGA) in older patients treated for cancer assesses several related domains, it does not include standardized biological tests. The present study aimed to: (1) assess the prognosis value of the B12/CRP index (BCI) in a population of systemically treatable older patients with cancer and (2) analyze the association between BCI value and pre-existing geriatric frailty.
METHOD
METHODS
We conducted a retrospective observational study between January 2016 and June 2020 at Marseille University Hospital. All consecutive cancer patients aged 70 years and over before initiating systemic therapy were included.
RESULTS
RESULTS
Of the 863 patients included, 60.5% were men and 42.5% had metastatic stage cancer. Mean age was 81 years. The low-BCI group (≤10,000) had a significantly longer survival time than the mid-BCI (10,000 < BCI ≤ 40,000) and high-BCI (BCI > 40,000) groups (HR = 0.327, CI95% [0.26-0.42],
CONCLUSION
CONCLUSIONS
A BCI > 10,000 would appear to be a good biological prognostic factor for poor survival times and pre-existing geriatric impairment in older cancer patients before they initiate systemic treatment.
Identifiants
pubmed: 35008333
pii: cancers14010169
doi: 10.3390/cancers14010169
pmc: PMC8750046
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Geriatr Oncol. 2019 Mar;10(2):272-278
pubmed: 30049582
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
J Am Geriatr Soc. 1997 Jun;45(6):735-8
pubmed: 9180669
Nutr Cancer. 2000;37(1):36-40
pubmed: 10965517
J Clin Oncol. 2012 Jun 10;30(17):2128-33
pubmed: 22585687
J Am Geriatr Soc. 2005 May;53(5):917-8
pubmed: 15877584
J Clin Oncol. 2009 May 1;27(13):2217-24
pubmed: 19289618
Oncologist. 2020 Dec;25(12):e1980-e1989
pubmed: 32745312
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
J Clin Oncol. 2005 Oct 1;23(28):6865-72
pubmed: 16192578
J Natl Compr Canc Netw. 2021 Sep 20;19(9):1006-1019
pubmed: 34551388
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Clin Biochem. 2003 Nov;36(8):585-90
pubmed: 14636871
Clin J Oncol Nurs. 2008 Dec;12(6):941-9
pubmed: 19064388
Age Ageing. 1988 Jul;17(4):227-35
pubmed: 3177082
J Clin Oncol. 2013 Apr 10;31(11):1464-70
pubmed: 23460711
J Pain Symptom Manage. 2000 Aug;20(2):93-103
pubmed: 10989247
Age Ageing. 2019 Jul 1;48(4):601
pubmed: 31081853
Nutr Clin Pract. 2017 Oct;32(5):599-606
pubmed: 28825869
Mech Ageing Dev. 2007 Jan;128(1):92-105
pubmed: 17116321
Psychopharmacol Bull. 1988;24(4):709-11
pubmed: 3249773
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
Am J Clin Nutr. 2009 Feb;89(2):707S-11S
pubmed: 19116332
J Am Geriatr Soc. 2002 Dec;50(12):1947-54
pubmed: 12473005
Cancer. 1977 Sep;40(3):1348-53
pubmed: 902243
J Am Geriatr Soc. 2008 Oct;56(10):1926-31
pubmed: 18811613
J Geriatr Oncol. 2022 Jan;13(1):40-45
pubmed: 34330668
Support Care Cancer. 2013 Mar;21(3):775-83
pubmed: 22941117
J Pain Symptom Manage. 2010 Jul;40(1):e12-3
pubmed: 20619196
Ann Oncol. 2007 Aug;18(8):1395-9
pubmed: 17513884